A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Captopril

Angiotensin Converting Enzyme Inhibitor class · 7 generic manufacturers · 28 ANDAs filed at FDA.

First FDA approval1996-02-13
Generic availableYes · 7 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$7.1M in CY2024 Part D spend104K claims · 31K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.138/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.187
Across all dosage forms in distribution.
Highest NADAC
$0.292
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Captopril used for?

Captopril is a Angiotensin Converting Enzyme Inhibitor medication tracked in Medicare Part D.

Is there a generic for Captopril?

Yes. 28 ANDAs filed at FDA, 7 generic manufacturers currently shipping.

How much does my plan pay for Captopril?

Across 329 Part D plans, Captopril averages $0.187/unit (NADAC). Lowest available: $0.138/unit. Highest in distribution: $0.292/unit.

Is Captopril on the FDA shortage list?

No. Captopril is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Angiotensin Converting Enzyme Inhibitor4 alternatives in D1
01
Ramipril
Brand: Vostally
$0.053Lowest NADAC
8Generic mfrs
$27.4MCY24 Part D spend
Compare →
02
Trandolapril
Angiotensin Converting Enzyme Inhibitor
$0.190Lowest NADAC
3Generic mfrs
$2.0MCY24 Part D spend
Compare →
03
Trandolapril Tablets
Brand: Trandolapril
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Trandolapril and Verapamil
Angiotensin Converting Enzyme Inhibitor
Lowest NADAC
1Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.